State AR
Clinical Trials in Arkansas
Arkansas is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Arkansas and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 99 actively recruiting studies with Arkansas sites out of 99 registered in total. The busiest research areas in Arkansas are Schizophrenia, Acute Myeloid Leukemia, Atrial Fibrillation. Leading sponsors running trials in the state include SWOG Cancer Research Network, Novartis Pharmaceuticals, National Cancer Institute (NCI). By stage, Arkansas trials break down as Phase 1 (9), Phase 2 (25), Phase 3 (44), Phase 4 (4).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Arkansas
Schizophrenia (3)Acute Myeloid Leukemia (3)Atrial Fibrillation (2)Non-small Cell Lung Cancer (2)Dravet Syndrome (2)Malignant Solid Neoplasm (2)Stage III Pancreatic Cancer AJCC v8 (2)Stage IV Pancreatic Cancer AJCC v8 (2)Duchenne Muscular Dystrophy (2)Peanut Allergy (2)Type 2 Diabetes Mellitus (2)Malignant Melanoma (1)
Frequently Asked Questions — Clinical Trials in Arkansas
How many clinical trials are currently recruiting in Arkansas?
ClinicalMetric currently tracks 99 actively recruiting clinical trials with at least one location in Arkansas. The total number of registered studies—including active but not currently enrolling trials—is 99. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Arkansas?
Arkansas hosts clinical trials across a broad range of medical conditions, including Schizophrenia, Acute Myeloid Leukemia, Atrial Fibrillation, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Arkansas serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Arkansas?
To join a clinical trial in Arkansas, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Arkansas maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Arkansas
NCT06317649 Phase 2
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute M...
Condition
Acute Myeloid Leukemia
Enrollment
147 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT05939414 Phase 3
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Obse...
Condition
Oligometastatic Prostate Cancer (OMPC)
Enrollment
450 pts
Location
United States, Argentina, Australia
Sponsor
Novartis Pharmaceuticals
NCT07580898 Phase 1
Recruiting
Safety of MOON101 for the Treatment of Peanut Allergy
Condition
Peanut Allergy
Enrollment
40 pts
Location
United States
Sponsor
Moonlight Therapeutics, Inc.
NCT07225946 Phase 3
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metas...
Condition
Prostatic Neoplasms, Castration-Resistant
Enrollment
800 pts
Location
United States, Australia, Belgium
Sponsor
Janssen Research & Development
NCT07391774 Phase 3
Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy ...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
1,978 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT06959524 N/A
Recruiting
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Co...
Condition
Coronary Arterial Disease (CAD)
Enrollment
1,616 pts
Location
United States, Australia, China
Sponsor
Boston Scientific Corporation
NCT07220681 N/A
Recruiting
Integrated Health Care for PTSD
Condition
Posttraumatic Stress Disorder (PTSD)
Enrollment
300 pts
Location
United States
Sponsor
Veterans Medical Research Foun
NCT06318169 Phase 3
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With ...
Condition
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Enrollment
1,350 pts
Location
United States, Argentina, Australia
Sponsor
89bio, Inc.
NCT07278739 N/A
Recruiting
Testing an Educational Program to Improve Goals of Care Conversations Between Pa...
Condition
Malignant Solid Neoplasm
Enrollment
1,020 pts
Location
United States
Sponsor
SWOG Cancer Research Network
NCT07219615 Phase 2
Recruiting
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont...
Condition
Chronic Spontaneous Urticaria
Enrollment
200 pts
Location
United States, Bulgaria, Canada
Sponsor
Pfizer
NCT07743450 Phase 3
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Pa...
Condition
Obesity
Enrollment
1,560 pts
Location
United States, Czechia, Germany
Sponsor
Ascletis Pharma (China) Co., L
NCT05213676 Phase 4
Recruiting
De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia
Condition
Congenital Diaphragmatic Hernia
Enrollment
600 pts
Location
United States
Sponsor
The University of Texas Health
NCT06422923 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral...
Condition
Epilepsy, Temporal Lobe
Enrollment
10 pts
Location
United States
Sponsor
Neurona Therapeutics
NCT05932680 Phase 2
Recruiting
Limited-duration Teclistamab
Condition
Myeloma Multiple
Enrollment
75 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn
NCT07160634 Phase 3
Recruiting
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrop...
Condition
Duchenne Muscular Dystrophy
Enrollment
80 pts
Location
United States, Australia, Canada
Sponsor
Solid Biosciences Inc.
NCT06989112 Phase 3
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegos...
Condition
Endometrial Cancer
Enrollment
600 pts
Location
United States, Australia, Austria
Sponsor
AstraZeneca
NCT05502016 N/A
Recruiting
Family Model DSME in FBOs in the RMI
Condition
Diabetes Mellitus, Type 2
Enrollment
288 pts
Location
United States
Sponsor
University of Arkansas
NCT07768371 Phase 3
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
Condition
IgE-Mediated Food Allergy
Enrollment
576 pts
Location
United States
Sponsor
Novartis Pharmaceuticals
NCT07662109 Phase 3
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of E...
Condition
Type 2 Diabetes Mellitus
Enrollment
2,000 pts
Location
United States, Argentina, Brazil
Sponsor
AstraZeneca
NCT06958328 Phase 3
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Condition
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Enrollment
356 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT07218809 Phase 3
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy i...
Condition
Epithelial Ovarian Cancer
Enrollment
1,100 pts
Location
United States, Australia, Belgium
Sponsor
AstraZeneca
NCT06756607 N/A
Recruiting
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollm...
Condition
Cancer
Enrollment
500 pts
Location
United States
Sponsor
Eastern Cooperative Oncology G
NCT07172516 Phase 3
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associat...
Condition
Bipolar Disorder
Enrollment
400 pts
Location
United States, Bulgaria, Germany
Sponsor
Xenon Pharmaceuticals Inc.
NCT06246916 Phase 3
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Partic...
Condition
Melanoma
Enrollment
560 pts
Location
United States, Canada
Sponsor
Regeneron Pharmaceuticals
NCT07061964 Phase 2
Recruiting
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Rem...
Condition
Muscle Invasive Bladder Urothelial Carcinoma
Enrollment
111 pts
Location
United States
Sponsor
National Cancer Institute (NCI
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology